Tags : Lannett

Weekly Snapshot

PharmaShots Weekly Snapshots (Feb 08 – 12, 2021)

Visby’s POC COVID-19 Test Receives the US FDA’s EUA for Use in CLIA Waived Settings Published: Feb 12, 2020 | Tags: Visby, POC, COVID-19, Test, Receives, US, FDA, EUA, Use, CLIA, Waived, Settings Takeda Collaborates with Ensoma to Accelerate Next-Generation In Vivo Gene Therapies Published: Feb 12, 2020 | Tags: Takeda, Collaborates, Ensoma, Accelerate, Next-Generation, Vivo Gene […]Read More

Biosimilars

Lannett Expand its Partnership with HEC to Include Biosimilar Fast-Acting

Shots: The companies collaborated to co-develop Insulin aspart while Lannett granted exclusive US commercialization rights of insulin aspart to HEC Lannett will fund the clinical development requirements and will manage the clinical & regulatory steps specific for the FDA’s approval while HEC continues to develop the product and related manufacturing infrastructure. Both companies will share […]Read More

Biosimilars Insights+

Insights+ Key Biosimilars Events of June 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Mylan with its partners Lupin and Biocon received MAA for Nepexto (biosimilar, etanercept) in EU and the US FDA’s Approval for Semglee (biosimilar, insulin glargine) respectively Our team at PharmaShots has summarized 15 key events of the […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (Jun 08- 12, 2020)

 1. Medtronic Receives CE Mark for MiniMed 780G Insulin Pump to Treat Type 1 Diabetes                                                Published: Jun 11, 2020 | Tags: Medtronic, Receives, CE, Mark, MiniMed 780G, Insulin Pump, Treat, Type 1 Diabetes 2.  Takeda to Divest OTC and Select Non-core Assets to Celltrion for ~ $278M        Published: Jun 11, 2020 | Tags: Takeda, Divest, [&Read More

Biosimilars Insights+

Insights+ Key Biosimilars Events of December 2019

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency In Dec, 2019 Kamada signed a deal with Alvotech for commercialization of biosimilars in Israel while Techno Science also signed an agreement with Kishi Kasei for co-developing biosimilar aflibercept Mylan and Biocon launched its Ogivri (trastuzumab-dkst) in […]Read More